FDA Warns Again Of Rare Cancer Associated With TNF Blockers

FDA is asking for an additional round of label changes for the tumor necrosis factor inhibitor class, as a consequence of mounting evidence of cases of a rare and usually fatal type of lymphoma in patients taking the drugs.